With a diverse pipeline to back up its projects, Tetra Bio-Pharma wants to be the first Canadian pharmaceutical company to launch a cannabis-based drug in breakthrough pain. Bernard Fortier, CEO of Tetra Bio-Pharma, counts on the production of credible scientific data to overcome stigmas attached to medical cannabis and believes that Canada can be leading the way in that regard.
Bernard, you took over as CEO of Tetra Bio-Pharma in July of last year. How did you come to work for a natural health company focused on cannabinoid products after an extensive career in the pharma industry?
"Tetra Bio-Pharma wants to be the first company to see a dried cannabis drug become a real prescription drug"
